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Summary
Background: The aim of this study was to investigate the pharmacokinetic and pharmacodynamic parameters of oral salmon calcitonin (oSCT)
administered over 14 days to men and women presenting with osteoarthritis (OA).
Materials and methods: The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratiﬁed
study including 73 subjects aged 57e75 years. Patients had painful OA with a Kellgren and Lawrence index score of IeIII. Treatment alloca-
tions were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days. The morning dose was administered between
07:00 and 08:00 at least 30 min before breakfast. The second dose was administered 30 min before evening dinner. On treatment day 1 and
14, the morning dose was followed by 5 h of fasting, and blood samples and urine were collected immediately prior to dosing and according to
the protocol. Study parameters were: plasma sCT levels, bone resorption by CTX-I (serum C-terminal telopeptide of collagen type I), bone
formation by osteocalcin (serum OC), and cartilage degradation by CTX-II (urine C-terminal telopeptide of collagen type II) (clinicaltrials.gov
identiﬁer: NCT00486369).
Results: Doses of 0.8 mg compared with 0.6 mg produced signiﬁcantly higher Cmax and AUC0e4 hrs, of calcitonin, P¼ 0.03. This resulted in
signiﬁcant reductions in CTX-I and CTX-II, [P< 0.0001; P¼ 0.007]. No differences were observed between baseline and follow-up at day
14 in pharmacokinetic and pharmacodynamic parameters. Gender had no observable inﬂuence on results.
Conclusions: oSCT given twice daily with a pre-dinner and morning fasting dosing resulted in reductions in markers of bone resorption and
cartilage degradation.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis1.
Bone and cartilage degradation are normally tightly coupled
in the pathogenesis of OA1,2, in which subchondral bone
turnover, sclerosis of the subchondral plate, trabecular thin-
ning and articular cartilage loss are coupled processes2. At
present it is not well understood or documented which
parameters are initiators or drivers of this disease. At the
same time it is appreciated that synovial inﬂammation is of-
ten present and a possible driver in some later stages of
OA, illustrating the complex nature of the initiation and
progression of the disease1,3. In view of this interaction
between bone and cartilage compartments of the articular
joint, an optimal approach to counter the progression of
OA may be to target both bone and cartilage degeneration.
Calcitonin exerts potent anti-resorptive effects4e6. It is
a small, 32-amino-acid peptide, secreted in response to*Address correspondence and reprint requests to: M. A. Karsdal,
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150excess calcium in serum7. Salmon calcitonin (sCT) is
approved for the treatment of osteoporosis and other dis-
eases involving accelerated bone turnover7,8. The adminis-
tration of sCT has so far been limited to either the
subcutaneous or intranasal route9. Recent preclinical expe-
rience and preliminary data from clinical settings suggest
that calcitonin may have positive effects on both bone and
cartilage thereby countering the progression of OA10e12.
Major obstacles to oral delivery of proteins include the
high acid content of the digestive tract and the extensive
array of local proteases13. 5-CNAC (8-(N-2-hydroxy-
5-chloro-benzoyl)-amino-caprylic acid) is a molecule based
on the Eligen technology from Emisphere14,15. The Eligen
technology employs low-molecular-weight compounds that
interact weakly and non-covalently with proteins, increasing
their lipophilicity and, consequently, their ability to cross the
gastrointestinal epithelium14. The carrier 5-CNAC enhances
transcellular absorption, without compromising the integrity
of the intestinal epithelium15e17. The 5-CNAC molecule
interacts with calcitonin without changing it and forms an in-
soluble entity at low pH values, thereby reducing degrada-
tion by digestive tract peptidases14. In the upper part of
the intestine at higher pH, the complex dissolves and
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membrane14. Thereby sCT is partly protected from degra-
dation in the GI tract, resulting in systemic exposure of in-
tact peptide.
This oral formulation of 5-CNAC in combination with sCT
was demonstrated to be safe and efﬁcacious in a 3-month
phase-II study in healthy postmenopausal women9. How-
ever, the effects on bone and cartilage degradation param-
eters of this oral formulation have not been investigated in
patients with OA.
Tissue turnover may be assessed by biochemical
markers of tissue degradation18,19. Osteoclast-mediated
bone resorption is mainly mediated by cathepsin K20. The
protease activity of cathepsin K results in a speciﬁc degra-
dation fragment of collagen type I, CTX-I (C-terminal telo-
peptide of collagen type I)18,21. This fragment has been
extensively used as a surrogate measure of bone resorption
for in vitro, preclinical and clinical studies18,22. Cartilage
degradation may be assessed by measurements of the
C-terminal telopeptide of type II collagen (CTX-II). CTX-II
is generated by Matrix Metalloproteinase (MMP) activity
during cartilage degradation which occurs in inﬂammatory
arthritis and OA23,24. Circulating levels of CTX-II have
been shown to predict loss of cartilage assessed by mag-
netic resonance imagining (MRI)25, and high levels of
CTX-II have been shown to be associated with OA and pro-
gression of the disease18,26,27.
The primary objective of the current study was to investi-
gate the pharmacokinetic proﬁle of oral sCT in both men and
women with OA, by assessing Cmax and AUC0e4 of oral sCT
(SMC021) following twice-daily dosing with 0.6 mg and
0.8 mg. In addition, the pharmacodynamic properties were
evaluated by the biochemical parameters of bone resorption
(serum CTX-I), bone formation (serum osteocalcin (OC)),
and cartilage degradation (urine CTX-II), calculated as the
area under the curve of the percentage change from base-
line. The pharmacokinetic and pharmacodynamic parame-
ters at day 1 were compared with those of day 14.Materials and methodsDRUG SUBSTANCEThe study drug was an oral formulation of sCT (SMC021) consisting of the
peptide hormone and 5-CNAC a unimolecular enhancer of gastrointestinal
peptide absorption. The moiety was designed to deliver sCT orally without
signiﬁcant enzymatic hydrolysis or alteration of the biological characteristics
of sCT. When 5-CNAC is administered orally in combination with sCT, gas-
trointestinal absorption of sCT is markedly enhanced in rodents, monkeys
and humans. The sCT-5-CNAC formulation was provided by Novartis
Pharma AG, Basel, Switzerland.
The active tablets contained either 0.6 mg or 0.8 mg of sCT formulated
with 200 mg of 5-CNAC. The placebo tablets contained neither 5-CNAC
nor sCT. The two doses of SMC021 were non-identical in appearance.
Two placebo tablets were used, each of which appeared identical to one
of the SMC021 doses. Due to the double-dummy design, participants took
two tablets (one study drug and one placebo; or two placebo pills) in the
morning and the same combination in the evening before dinner. Both tablets
were taken with a total of 50 ml of water.STUDY DESIGNThe study was a phase-I, 2-week, placebo-controlled, double-blind,
double-dummy, randomized, gender-stratiﬁed study including 73 subjects.
Of these, 37 were postmenopausal women and the remaining 36 were
men. The study subjects fulﬁlled the inclusion criteria of being generally
healthy, aged 57e75 years, and the women had passed a natural or surgi-
cal menopause at least 2 years before entering the study. At inclusion the
subjects had painful OA of at least one knee, i.e., had knee pain for most
days of the previous month, and experienced either morning stiffness of
less than 30 min, or had crepitus. Additionally, the painful knee had to
have a Kellgren and Lawrence (KL) index score of IeIII. The subjects didnot have diseases or medications, such as bisphosphonates, known to af-
fect bone metabolism.
After consenting, the subjects were randomized to one of three treatment
arms: treatment with 0.6 mg of sCT (12 women and 12 men), or 0.8 mg of
sCT (13 women and 13 men), or placebo (12 women and 11 men). Random-
ization was performed by Novartis Drug Supply Management using a vali-
dated system. Each treatment was given twice daily for 14 days. The
morning dose was administered between 07:00 and 08:00 at least 30 min
before breakfast, except on days 1 and 14 when the 08.00 dose was
followed by fasting for 5 h. The second dose was administered 30 min
(days 2e13 inclusive) or 60 min (days 1 and 14) before evening dinner.
The study period included an initial screening visit, a treatment period of
14 days with pharmacokinetic/pharmacodynamic (PK/PD) assessments at
baseline, prior to treatment on treatment day 1, and again on day 14. Visits
were scheduled on day 2, after 1 week of treatment, on treatment day 14 for
a PK/PD assessment, and on day 15. On the ﬁrst day of treatment, the sub-
jects arrived at the clinic after an overnight fasting period and received the
ﬁrst dose of study drug at 08:00. The subjects remained fasting until lunch
that was served at 13.00. A light meal was eaten at 15:30, the second
dose was given at 17:00, and dinner was served 1 h later at 18:00. The
same dosing and meal schedule was applied on treatment day 14.
The safety and tolerability of oral salmon calcitonin (oSCT) was assessed
by a review of adverse experiences reports, physical examinations, vital
signs of blood pressure, heart beat rate, ECG, and clinical laboratory safety
tests of blood, urine, and faeces samples.
The subjects did not have diseases or received medications known to
affect bone and cartilage metabolism. Before and during the study none
received any of the prohibited medication which included glucosamine, cal-
citonin, intraarticular corticosteroid or hyaloronic acid injections, oral or intra-
venous bisphosphonate, ﬂuoride, strontium, PTH or PTH derivatives,
anabolic steroids or testosterone, glucocorticosteroids, systemic hormone
replacement therapy, selective estrogen receptor modulators (SERMs), or
Tibolone. One of the subjects in the placebo group used an anti-epileptic
drug containing pregabalin, none of the other subjects received anti-epilep-
tics. NSAID was used by eight subjects in the 0.8 mg treatment group, seven
subjects in the 0.6 mg group, and six subjects in the placebo group.
For the evaluation of pharmacokinetics, blood samples were collected
immediately prior to dosing (time 0 min), and at intervals of 10, 15, 30, 45,
60, 120, and 240 min after morning and evening dosing. For evaluation of
pharmacodynamics, blood samples were collected immediately prior to dos-
ing (time 0 h), and at intervals of 1/2, 1, 2, 4, 6 and 8 h after morning dose
and, for the pre-dinner dose, immediately prior to dosing (time 0 h), and at
the intervals of 1/2, 1, 2, and 4 h post-dose. Urine samples were collected
pre-dose and at 2, 4, 6, 8, 11, and 13 h after the morning dose. All samples
were stored at e20C until analysis.BIOCHEMICAL ASSAYSThe concentration of plasma sCT was measured as previously de-
scrived10,28. Serum CTX-I was determined by the Serum CrossLaps One
Step ELISA, serum OC (sOC) by the Serum N-MID OC ELISA, and urinary
CTX-II was determined using the Urine Cartilaps ELISA (IDS Nordic, Herlev,
Denmark). Urinary creatinine was measured by the routine chemistry method
and used for the calculation of creatine-corrected urinary CTXII
concentrations.
The study was conducted in accordance with Helsinki Declaration II ver-
sion II. The study was approved by the local Danish Ethical Committees, and
conducted in Ballerup and Vejle, Denmark in January to February 2007
(clinicaltrials.gov identiﬁer: NCT00486369).STATISTICAL ANALYSISVarious scenarios were applied in the determination of sample size. The
scenario requiring the largest study population was based on demonstrating
a difference between 0.6 mg and 0.8 mg sCT given as a morning dose in the
treatment effect of serum CTX AUC if the difference was more than 30%.
Assuming that the placebo-adjusted treatment effect of 0.8 mg sCT was
115% hrs, placebo-adjusted treatment effect of 0.6 mg sCT was
80% hrs (¼115*0.7), a common standard deviation of 25% hrs,
a sample size of 24 subjects (12 in each sCT group) was required to reject
the null hypothesis of a 2-sided t-test at a power of 90% and signiﬁcance
level of 5%. To allow gender-speciﬁc assessment it was aimed at having
12 subjects of each gender in each treatment group giving a total sample
size of 72 subjects.
All randomized subjects were analyzed. No imputing of missing data was
performed. The trapezoidal method was applied for calculation of the area
under the concentration-time curve (AUC) of plasma sCT and changes in
serum CTX-I (sCTX-1) and sOC after dosing. AUC of the change in urinary
CTX-II (uCTX-II) was calculated as the change multiplied by the time period
representing the sample, i.e., the time period elapsed since previous sample.
To assess changes in sCTX-I, sOC, and uCTX-II after dosing, values were
calculated for each person and expressed relative to the 08:00 pre-dose
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time course data of plasma sCT, sCTX-I, sOC, and uCTX-II were logarithmi-
cally transformed to obtain normality and symmetry of variances.
A non-compartmental pharmacokinetic analysis was performed for calcu-
lation of the elimination half-life (T1/2) associated with the terminal slope (lz)
of a semilogarithmic concentration-time curve using WinNonLin version 5.2.
The elimination half-life was estimated as ln2/lz. Plasma sCT values below
the lower limit of quantiﬁcation of 2.5 pg/ml were assigned the value of
2.5 pg/ml in the calculation of the AUC of plasma sCT and Cmax, In the phar-
macokinetic evaluation the non-parametric Wilcoxon test was used for
comparison of Tmax values between the two groups receiving sCT, and the
two-tailed Student’s t-test was applied for the pairwise comparison of AUC
of sCT, Cmax, and T1/2.
Treatment responses in sCTX-I and uCTX-II were assessed by ANOVA,
and the level of signiﬁcance was TukeyeCramer adjusted in the multiple
comparisons. The tests for the primary endpoints and others were consid-
ered to be descriptive and hypothesis generating tests and no adjustments
were performed for multiple endpoints.
A difference was considered signiﬁcant if a P-value was less than 5%. All
statistical calculations were performed using the SAS software package
(release 9.1, SAS Institute Inc., Cary, NC, USA).Results
No serious adverse events were reported by any of the
subjects. During treatment a total of 44 volunteered
adverse events were reported. Among the 15 adverse
events associated with the gastrointestinal system, three
of the occasions were assessed related to study drug in
the 0.6 mg group; two in the 0.8 mg group, and two in the
placebo group. The one ﬁnding of clinical signiﬁcant impor-
tance of ECG’s was observed in a subject in the placebo
group. The physical examinations did not reveal any
changes in ﬁndings of importance, and there were no
adverse events reported from the monitoring of vital signs.
The analysis of the blood pressure did not reveal any signif-
icant differences in any of the treatment groups as com-
pared with the placebo group at any time points. A
transient increase in heart beat rate was observed for the
0.8 mg group at day 7. Analysis of the laboratory safety
data for serum chemistry, haematology, urine safety, andTable
Baseline demographic characte
Placebo
Gender Females n¼ 12
Males n¼ 11
Age (yrs)* Females 65.7 (4.1)
Males 64.6 (3.7)
Height (cm)* Females 168.2 (5.1)
Males 177.8 (7.1)
Weight (kg)* Females 76.4 (15.2)
Males 89.0 (15.2)
BMI (kg/m2)* Females 27.0 (5.6)
Males 28.2 (5.1)
KL index 1: 7 (30%)
2: 8 (35%)
3: 8 (35%)
sCTX-I (ng/ml)y Females 0.76 (0.53e1.0
Males 0.54 (0.41e0.7
sOC (ng/ml)y Females 18.5 (13.1e26
Males 13.4 (11.3e15
uCTX-II (ng/mmol)y Females 303 (161e570
Males 278 (200e387
*Values given are arithmetic mean (SD).
yValues given are geometric mean (1SD range).faeces did not indicate any drug-related functional or toxic
effects on speciﬁc organs.
The demographic characteristics of the study subjects
within each treatment group are given in Table I. The sub-
jects were aged between 57 and 75 years and ranged in
body mass index between 19.5 and 38.9. A total of 32%
of the subjects (n¼ 23) had a KL-score of I, 42% (n¼ 31)
had a KL-score of II, and 26% (n¼ 19) had a KL-score of
III. Females had signiﬁcantly higher baseline values of
sCTX-I (P¼ 0.04) and sOC (P¼ 0.007), and borderline sig-
niﬁcantly higher baseline values of urinary CTX-II
(P¼ 0.06). One subject in the placebo group withdrew
from the study on treatment day 2 because of non-compli-
ance with required dietary restrictions during study, and
one subject in the 0.6 mg sCT group withdrew after 7
days of treatment because of general discomfort. The
remaining 71 subjects completed the study programme.
A study ﬂow diagram is shown in Fig. 1.PHARMACOKINETICSThe pharmacokinetic proﬁle of SMC021 was assessed by
measurement of sCT in blood samples drawn at scheduled
time points in the 4 h following drug administration at 08:00
and at 17:00 on treatment day 1 and treatment day 14.
Figure 2 shows the time course of the plasma sCT concen-
trations, Fig. 3 the AUC of plasma sCT in the 4 h post-dos-
ing, and Table II gives the pharmacokinetic parameters of
AUC0e4 hrs; Cmax, Tmax, and the elimination half-life T1/2.
On the ﬁrst day of dosing, AUC0e4 hrs of plasma sCT
reached 2905 [pg/mlmin] in the group receiving 0.6 mg,
and 5242 [pg/mlmin] in the 0.8 mg group, and the maxi-
mum peak concentration, Cmax, obtained was 81 pg/ml
and 170 pg/ml respectively. The difference in both AU-
C0e4 hrs and Cmax was statistically signiﬁcant between the
two dosing groups (P¼ 0.03). No difference was seen in re-
sults between women and men. After dosing at 08:00 on
day 1 the median time to reach maximum concentration,I
ristics of study population
0.6 mg sCT 0.8 mg sCT
n¼ 12 n¼ 13
n¼ 12 n¼ 13
64.5 (4.4) 66.7 (4.1)
65.3 (1.4) 64.0 (4.0)
167.2 (7.7) 161.9 (5.5)
176.9 (6.1) 175.5 (7.9)
73.4 (10.3) 78.7 (13.5)
85.2 (9.0) 91.9 (17.0)
26.4 (4.1) 29.9 (3.9)
27.2 (2.4) 29.7 (4.4)
1: 7 (29%) 1: 9 (35%)
2: 11 (46%) 2: 12 (46%)
3: 6 (25%) 3: 5 (19%)
7) 0.67 (0.50e0.89) 0.56 (0.38e0.82)
0) 0.59 (0.35e0.98) 0.50 (0.34e0.75)
.2) 17.5 (12.8e23.9) 15.3 (11.1e21.2)
.9) 15.1 (10.4e21.9) 13.3 (10.2e17.4)
) 410 (268e626) 293 (192e449)
) 256 (159e411) 263 (153e455)
Assessed for eligibility  (n=91)
Excluded (n=18)
Not meeting inclusion criteria (n=14)
Refused to participate (n=0)
Other reasons (n=4)
Randomized (n=73)
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SMC021 – absorption, efficacy and tolerance in patients with osteoarthritis. 
A placebo-controlled 14-days study
Allocated to 0.6 mg sCT (n=24)
Received intervention (n=24)
Did not receive intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=1), 
general discomfort
Analyzed (n=24)
Excluded from analysis (n=0)
Allocated to 0.8 mg sCT (n=26)
Received intervention (n=26)
Did not receive intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analyzed (n=26)
Excluded from analysis (n=0)
Allocated to Placebo (n=23)
Received intervention (n=23)
Did not receive intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=1),  
non-compliance with dietary 
restrictions
Analyzed (n=23)
Excluded from analysis (n=0)
Fig. 1. Flow diagram giving the number of subjects screened, number of subjects allocated, number of subjects at follow-up, and number of
subjects analyzed.
153Osteoarthritis and Cartilage Vol. 18, No. 2Tmax was 15 min in the 0.6 mg SMC021 group and 30 min in
the 0.8 mg group (P¼ 0.02). The elimination half-life, T1/2,
was comparable for the two doses, being 12.1 min and
11.3 min, respectively (P¼ 0.70). The pharmacokinetic pro-
ﬁles of the 08:00 dosing on day 14 was similar to that of
day 1 for both doses, in terms of AUC0e4 hrs, Cmax, Tmax,
and T1/2.
Compared with dosing at 08:00 followed by 5-hour fasting,
dosing at 17:00 1 h before dinner was associated with about
half the absorption of SMC021 in terms of AUC0e4 hrs. Corre-
spondingly the maximum peak concentration, Cmax reached
about one third of that achieved with the 08:00 dose. The
time to reach maximum peak concentration in both groupsreceiving the pre-dinner dose at 17:00 was 30 min, and the
elimination half-life T1/2 of this dose was comparable among
the two dosing groups (P¼ 0.40) and not different from the
T1/2 of the 08:00 dosing. A signiﬁcant dose-dependency in AU-
C0e4 hrs was observed at dosing day 14 (P¼ 0.05). The differ-
ence was non-signiﬁcant at dosing day 1 (P¼ 0.40).PHARMACODYNAMIC EFFICACY PARAMETER OF SCTX-IFigure 4 shows the time course of sCTX-I relative to the pre-
dose concentration. The two doses of 0.6 mg and 0.8 mg of
sCT were comparably efﬁcient in suppression of the bone re-
sorption marker sCTX-I. Following the morning dose at 08:00,
Plasma CT at Day 1
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Dose at 08:00 and 17:00
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Fig. 2. Time course of plasma sCT concentrations in the 4 h follow-
ing dosing with 0.6 mg sCT (open circles), 0.8 mg sCT (closed cir-
cles), and placebo (dotted line). Upper panel is dosing at treatment
day 1 with doses given at 08:00 and 17:00. Lower panel is dosing at
treatment day 14 with doses given at 08:00 and 17:00. Values
shown are geometric mean 1 S.E.M.
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Fig. 3. AUC of plasma sCT concentrations in the 4 h following dos-
ing at 08:00 (upper panel) and 17:00. (lower panel). Values shown
are geometric mean 1 S.E.M.
154 M. A. Karsdal et al.: The effect of oral sCT in OA patientssCTX-I was observed to bemaximally suppressed 2 h later at
10:00. At this time point of dosing on day 1, the mean level in
the placebo group was 88% in contrast to 34e35% in the sCT
groups. The suppression was transient, i.e., 8 h after dosing
sCTX-I in the sCT groups was at a level similar to that of the
placebo group. Following the pre-dinner dose at 17:00, the
maximum difference between placebo and the sCT groups
was also observed 2 h after dosing. A similar pattern of sup-
pression was observed after dosing on day 14.
The effect of the twice-daily dosing was assessed by AUC
of the relative change in the time period from 08:00 to 21:00
(Fig. 4). On both treatment days 1 and 14, the difference in
AUC between the sCT treatment groups and the placebo
group was highly statistically signiﬁcant (P< 0.0001), but
there was no statistically signiﬁcant difference between the
sCT treatment groups. There was no statistically signiﬁcant
effect of gender in the effect on sCTX-1.PHARMACODYNAMIC EFFICACY PARAMETER OF UCTX-IIFigure 5 shows the time course of uCTX-II relative to the
pre-dose concentration and the AUC of the relative changein uCTX-II in the time period from 08:00 to 21:00. The two
doses of 0.6 mg and 0.8 mg of sCT were comparably highly
efﬁcient in suppression of the cartilage resorption marker of
uCTX-II. Following the morning dose at 08:00 on treatment
day 1, uCTX-II excretion was maximally suppressed in the
samples obtained 4 h and 6 h after dosing. The uCTX-II
did not return to pre-dose levels but continued to be sup-
pressed during the 13-hour observation period. The differ-
ence in AUC0e13 hrs of the relative change of uCTX-II in
the sCT treatment groups and the placebo group was highly
signiﬁcant on both dosing days respectively (P¼ 0.007,
P< 0.0001). There were no statistically signiﬁcant differ-
ences in the AUCs between the two sCT groups, and there
was no statistically signiﬁcant impact of gender.PHARMACODYNAMIC EFFICACY PARAMETER OF sOCFigure 6 shows the time course of sOC relative to the pre-
dose concentration. The two doses of 0.6 mg and 0.8 mg of
sCT showed a marginal suppression of the bone formation
marker sOC that was signiﬁcant on treatment day 1 but not
on treatment day 14. There was no statistically signiﬁcant
difference between the sCT treatment groups, and there
was no statistically signiﬁcant effect of gender in the effect
on sOC.
Table II
Pharmacokinetic parameters at treatment day 1
0.6 mg sCT 0.8 mg sCT P-value
Dosing at 08:00
AUC0e4 h (pg/mlmin)* 1SD range 2905 (1043e8086) 5242 (2197e12,505) 0.03
Cmax (pg/ml)* 1SD range 81 (22e294) 170 (63e459) 0.03
Tmax (min)y Q1eQ3 range 15 (15e30) 30 (15e30) 0.02
T1/2 (min)z 1SD range 12.1 (9.5e16.7) 11.3 (7.7e20.9) 0.70
Dosing at 17:00
AUC0e4 h (pg/mlmin)* 1SD range 1987 (740e5338) 2520 (948e6701) 0.40
Cmax (pg/ml)* 1SD range 32 (8e126) 52 (14e195) 0.21
Tmax (min)y Q1eQ3 range 30 (30e30) 30 (30e30) 0.81
T1/2 (min)z 1SD range 11.4 (8.4e17.8) 10.8 (7.5e18.8) 0.40
*Values given are geometric mean (1SD range).
yValues given are median (Q1eQ3 range).
zValues given are mean (1SD range).
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Presently, no oral formulations of peptides or proteins are
approved by the Food and Drug Administration (FDA) in the
US and the European Medicines Agency (EMEA). This may
in part be due to the lack of knowledge about parameters
affecting intact peptides passing through the gastric tract
and subsequent uptake over the intestinal barriers. Thus,
there is a need for the presentation of systematic studies
with oral peptide formulations that may aid other re-
searchers in obtaining optimal pharmacokinetic and phar-
macodynamic parameters.
Recently, a new oral formulation of calcitonin in combina-
tion with the carrier molecule 5-CNAC has been tested clin-
ically9,10. An extensive array of interactions with this oral
formulation has been tested in healthy volunteers or pa-
tients with osteoporosis, including but not limited to the in-
teraction with food intake29, interaction with water
intake30, dosing at different time points during the day due
to the strong circadian variation in bone resorption31, and ﬁ-
nally a synthetic vs a recombinant form of calcitonin32. The
main conclusions drawn from these studies was optimal ef-
ﬁcacy with this oral formulation was achieved by (1) dosing
at least 10 min prior to a meal compared to postprandial
dosing (2) tablets given with 50 ml of water resulted in a sig-
niﬁcant better exposure and response in biochemical
markers of surrogate efﬁcacy (CTX-I) compared to that of
200 ml of water (3) dosing in the evening resulted in signif-
icant increased response in biochemical markers of surro-
gate efﬁcacy compared to the morning, due to the
circadian variation in bone resorption that peaks during
the evening and night (4) A recombinant formulation of
sCT provided similar efﬁcacy parameters compared to
that of a synthetic version.
In term of the pharmacokinetic parameters, an almost
similar proﬁle with equal Tmax and T1/2, was observed with
this oral formulation when compared to the nasal formula-
tion in a head to head study30. However the Cmax, and
from that the AUCsCT was more than ten fold higher with
this oral formulation. As the AUC of sCT was directly linear
proportional to the effect on bone resorption, CTX-I30, this
resulted in a signiﬁcantly better inhibition of bone resorp-
tion30. However, even in the face of these careful investiga-
tions and conclusions, a systematic study of the effects of
this oral formulation in both men and women presenting
with clinical symptoms of OA have not been presented.
The present investigations suggested almost similar
pharmacokinetic properties of 0.8 vs 0.6 mg sCT, albeit
with small differences. As expected the 0.8 mg formulationresulted in signiﬁcantly higher Cmax and subsequently
a larger AUC. Dosing in the morning, followed by 5-hour
fasting, resulted in higher Cmax and subsequently a larger
AUC compared with the evening dose which was followed
by dinner 1 h later. Only the morning doses of 0.6 mg re-
sulted in a shortened time until Tmax, 15 vs 30 min, com-
pared with the 0.8 mg fasting dose. This circadian
difference in the morning compared to the evening effect
on Cmax and Tmax is not understood at the present time
and needs further investigation.
With regards to pharmacodynamic parameters of efﬁ-
cacy, i.e., bone resorption and cartilage degradation, com-
parable effects were observed both at days 1 and 14 and
with both 0.6 and 0.8 mg dosing. This is in contrast to pre-
vious studies in which clear dose-response relationships
have been observed up to 1.0 mg9,10. Those studies
were, however, performed with single doses in which the ef-
fect on pharmacodynamic efﬁcacy was lost after a maximum
of 12 h due to the short half-life of sCT7,30.
In this current study we did not detect differences be-
tween the pharmacokinetic and pharmacodynamic proper-
ties of sCT at day 1 compared with those of day 14. This
is in complete alignment with other data obtained with this
oral formulation in which similar effects of pharmacody-
namic parameters were observed at day 1, compared with
those at 1 and 3 months9, albeit in contrast to some specu-
lations on a so-called escape phenomena33. Whether this,
in part, is due to the route of administration, nasal or i.v.
compared with oral, remains to be investigated, albeit this
opens highly interesting opportunities for other peptides,
with which tachyphylaxis have been observed and possibly
deterred further development.
In the present study we did not detect different effects on
pharmacodynamic parameters, CTX-I and uCTX-II, of sCT
dosing between men and women, and the current pharma-
cokinetic/pharmacodynamic parameters are comparable to
those published previously in healthy postmenopausal
women9,10.
At baseline we observed signiﬁcantly increased levels of
uCTX-II in women compared with those of men. This is in
alignment with previous investigations comparing premeno-
pausal and postmenopausal women34, suggesting that es-
trogen deﬁciency may increase cartilage degradation
whereas estrogen replacement may positively affect the
pathogenesis of OA2,35e37.
Previous investigations of the effect on bone and carti-
lage metabolism of anti-resorptive agents in clinical settings
have suggested that higher dosing is needed to sustain
a decrease in CTX-II compared with that of CTX-I. This
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Fig. 4. Time course and AUC of serum CTX-I following dosing with
0.6 mg sCT (open circles), 0.8 mg sCT (closed circles), and placebo
(dotted line). Upper panel is dosing at treatment day 1 with doses
given at 08:00 and 17:00. Middle panel is dosing at treatment day
14 with doses given at 08:00 and 17:00. Values shown are levels rel-
ative to the pre-doseconcentrationmeasured in blood samples taken
immediately prior to dosing at 08:00. Lower panel gives the AUC of
the change in relative levels from 08:00 to 21:00 Values given are
mean 1 S.E.M. TukeyeKramer adjusted signiﬁcance levels of treat-
ment effect against placebo: ***P< 0.001.
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Fig. 5. Time course and AUC of urine CTXII following dosing with
0.6 mg sCT (open circles), 0.8 mg sCT (closed circles), and pla-
cebo (dotted line). Upper panel is dosing at treatment day 1 with
doses given at 08:00 and 17:00. Middle panel is dosing at treatment
day 14 with doses given at 08:00 and 17:00. Values shown are
levels relative to the pre-dose concentration measured in blood
samples taken immediately prior to dosing at 08:00. Lower panel
gives the AUC of the change in relative levels from 08:00 to
21:00 Values given are mean 1 S.E.M. TukeyeKramer adjusted
signiﬁcance levels of treatment effect against placebo: **P< 0.01;
***P< 0.001.
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Fig. 6. Time course and AUC of serum OC following dosing with
0.6 mg sCT (open circles), 0.8 mg sCT (closed circles), and pla-
cebo (dotted line). Upper panel is dosing at treatment day 1 with
doses given at 08:00 and 17:00. Middle panel is dosing at treatment
day 14 with doses given at 08:00 and 17:00. Values shown are
levels relative to the pre-dose concentration measured in blood
samples taken immediately prior to dosing at 08:00. Lower panel
gives the AUC of the change in relative levels from 08:00 to
21:00 Values given are mean 1 S.E.M. TukeyeKramer adjusted
signiﬁcance levels of treatment effect against placebo:
***P< 0.001.
157Osteoarthritis and Cartilage Vol. 18, No. 2was the case for SERMs and bisphosphonates38,39. Even
an increase in CTX-II has been observed to be associated
with strongly suppressed CTX-I levels with the synthetic
steroid tibolone40. This suggests that some, but not all,
anti-resorptives can have a positive secondary effect on
cartilage metabolism. In addition this suggests that bone
and cartilage metabolism are coupled under some condi-
tions but not under others2,40,41.
The pathogenesis of OA involves both bone and cartilage
changes2,42e46. At present it is not well understood or docu-
mented which parameters are initiators or drivers of this dis-
ease. At the same time it is appreciated that synovial
inﬂammation is often present and a possible driver in some
later stages of OA, illustrating the complex nature of the initi-
ation and progression of the disease1,3. An optimal approach
to counter theprogressionofOAmayoptimally affect the cells
of both bone and cartilage. Calcitonin has been shown to
have positive effects on both osteoclasts and chondro-
cytes47, and to counter the progression of OA inmost preclin-
ical models of OA48e52. In addition, it has shown promise in
preliminary clinical settings10e12,28. Further investigations in
clinical trials are needed to validate the potential positive ef-
fect of calcitonin on the pathogenesis of OA.
Conclusion
In conclusion, twice daily 0.6 mg or 0.8 mg doses of oral
sCT was well tolerated and safe and suppressed markers of
cartilage and bone degradation signiﬁcantly. Oral sCT may
be a potential therapeutic for women and men with OA. This
hypothesis needs validation in long-term human trials on
relevant clinical endpoints recommended by agencies.Conﬂicts of interest
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